Evidence map›Paper›PMID 40092929›Full record

ArticleWorld journal of gastrointestinal oncology2025

IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression

Jin Zhou, Jing-Rui Chen, Jin-Ming Li, Shuang-Qing Han, Xi-Yue Deng, Zhong-Min Li, Wen Tong, Chao Wang, Yi Bai, Ya-Min Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jin ZhouThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Jing-Rui ChenThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Jin-Ming LiThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Shuang-Qing HanThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Xi-Yue DengThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Zhong-Min LiDepartment of Hepatobiliary and Pancreatic Surgery, Tianjin Nankai Hospital, Tianjin 300070, China.
Wen TongThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Chao WangThe First Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Yi BaiDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300070, China.
Ya-Min ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300070, China. zhangyamin@nankai.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

aimTo determine the mechanism of the IL-22/IL-22R1 pathway in CCA and provide new directions for its clinical treatment.

methods

results

conclusionThe IL-22/IL-22R1 axis promotes CCA progression by activating ERK1/2 signaling. Targeting this pathway with ERK1/2 inhibitors offers potential therapeutic strategies for CCA.

Indexed as

Cancer progressionCholangiocarcinomaERK1/2IL-22IL-22R1

Identifiers

PMID40092929
PMCPMC11866239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.